MacroGenics, Inc. is a biopharmaceutical company focused on discovering and developing antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops new therapeutic product candidates using its antibody-based technology platforms and also in partnership with other biopharmaceutical companies. MacroGenics has a pipeline of product candidates in human clinical testing, primarily against various cancers. These include two product candidates developed using Fc Optimization platform, namely margetuximab, an antibody for the treatment of certain types of metastatic breast cancers and gastroesophageal cancers, and MGA271, an antibody to impact various tumors through multiple potential mechanisms of action. In addition, the Company has created different product candidates based on Dual-Affinity Re-Targetingr (DART) platform.

TypePublic
HQRockville, US
Founded2000
Size (employees)330 (est)+4%
Websitemacrogenics.com
MacroGenics was founded in 2000 and is headquartered in Rockville, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at MacroGenics

Scott Koenig

Scott Koenig

President & Chief Executive Officer and Board Member
Ezio Bonvini

Ezio Bonvini

Senior Vice President, Research
Eric Risser

Eric Risser

Vice President, Development
James Karrels

James Karrels

Vice President, Chief Financial Officer
Lynn Cilinski

Lynn Cilinski

Vice President, Controller and Treasurer
Show more

MacroGenics Office Locations

MacroGenics has offices in Rockville and South San Francisco
Rockville, US (HQ)
9640 Medical Center Dr
Rockville, US
15235 Shady Grove Rd
South San Francisco, US
1 Corporate Dr
Show all (3)
Report incorrect company information

MacroGenics Financials and Metrics

MacroGenics Revenue

MacroGenics's revenue was reported to be $157.74 m in FY, 2017
USD

Revenue (Q3, 2018)

20.8m

Net income (Q3, 2018)

(34.0m)

EBIT (Q3, 2018)

(35.0m)

Market capitalization (14-Dec-2018)

578.5m

Closing stock price (14-Dec-2018)

13.7

Cash (30-Sep-2018)

201.8m
MacroGenics's current market capitalization is $578.5 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

58.0m47.8m100.9m91.9m157.7m

Revenue growth, %

(18%)111%(9%)

General and administrative expense

11.1m22.8m29.8m32.7m

R&D expense

46.6m98.3m122.1m147.2m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

20.2m14.7m9.2m18.4m71.3m6.7m14.7m2.8m80.7m3.3m2.1m1.7m1.7m4.7m18.8m20.8m

General and administrative expense

2.0m3.3m4.1m3.7m4.7m5.3m6.0m6.1m7.2m7.2m7.5m8.4m8.4m9.2m11.1m9.6m

R&D expense

11.1m14.6m17.3m18.6m21.5m22.7m24.1m27.3m33.3m30.3m32.8m34.5m41.0m45.7m52.0m46.2m

Operating expense total

13.1m17.8m21.5m22.3m26.1m28.0m30.1m33.5m40.6m37.5m40.3m42.8m49.4m54.9m63.1m55.8m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

116.5m157.6m196.2m84.1m211.7m

Accounts Receivable

2.0m2.9m1.2m2.8m13.6m

Inventories

Current Assets

119.5m164.7m342.4m283.9m322.3m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

33.6m198.7m194.0m179.2m263.1m235.0m365.8m152.0m62.3m109.9m40.5m116.6m90.9m200.4m238.7m201.8m

Accounts Receivable

2.3m1.7m2.6m5.3m1.7m4.3m2.7m2.5m78.4m3.0m2.1m2.0m2.2m7.3m17.8m21.0m

Current Assets

37.0m202.4m198.8m187.0m268.5m242.4m370.5m309.3m348.4m316.3m251.0m250.1m209.5m271.0m322.1m285.6m

PP&E

4.5m5.1m5.4m5.6m7.2m9.4m11.5m14.3m18.3m18.5m17.4m23.2m30.8m53.4m57.5m58.6m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(260.8k)(38.3m)(20.1m)(58.5m)(19.6m)

Depreciation and Amortization

1.2m1.8m2.9m7.6m7.2m

Inventories

Accounts Payable

(570.1k)(1.5m)(163.0k)2.2m(1.5m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

2.9m(3.1m)(15.4m)(19.3m)(30.4m)10.1m(23.7m)(37.7m)(78.3m)(125.4m)(49.5m)(92.8m)(126.8m)

Depreciation and Amortization

834.6k398.2k835.0k1.3m546.0k1.2m1.7m1.8m3.6m5.6m2.0m4.0m5.9m1.3m2.5m5.3m

Accounts Payable

(1.9m)2.0m808.0k1.2m(225.0k)184.0k872.0k(388.0k)(355.0k)(133.0k)(2.2m)(2.0m)(2.1m)7.8m(684.0k)(1.5m)

Cash From Operating Activities

(13.0m)5.9m1.7m(12.6m)43.6m18.1m10.5m(31.9m)(65.1m)(15.3m)(35.3m)(66.1m)(97.4m)(31.3m)(89.0m)(126.0m)
USDY, 2018

Financial Leverage

1.3 x
Show all financial metrics
Report incorrect company information

MacroGenics News and Updates

MacroGenics Announces Partial Clinical Hold on MGD009 Phase 1 Studies

ROCKVILLE, MD, Dec. 07, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that on December 6, it received a lett…

Trianni, Inc. and MacroGenics, Inc. Announce License Agreement

SAN FRANCISCO and ROCKVILLE, Md., Dec. 6, 2018 /PRNewswire/ -- Trianni, Inc. ("TRIANNI") and MacroGenics, Inc. (Nasdaq: MGNX) today announced that they have entered into a license agreement for The Trianni Mouse™, a best-in-class transgenic mouse R&D platform for the discovery of...

MacroGenics and Zai Lab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Margetuximab, MGD013 and TRIDENT™ Molecule in Greater China

ROCKVILLE, MD, and SHANGHAI, China, Nov. 29, 2018 (GLOBE NEWSWIRE) --   MacroGenics (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, and Zai Lab Limited (NASDAQ: ZLAB), a …

MacroGenics Reports Presentation of Clinical Data at 33rd Annual SITC Meeting

ROCKVILLE, MD, Nov. 09, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the presentation of clinical data in o…

MacroGenics Provides Update on Corporate Progress and 3rd Quarter 2018 Financial Results

ROCKVILLE, Md., Nov. 07, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corporate progress and…
Show more
Report incorrect company information

MacroGenics Company Life and Culture

Report incorrect company information

MacroGenics Frequently Asked Questions

  • When was MacroGenics founded?

    MacroGenics was founded in 2000.

  • Who are MacroGenics key executives?

    MacroGenics's key executives are Scott Koenig, Ezio Bonvini and Eric Risser.

  • How many employees does MacroGenics have?

    MacroGenics has 330 employees.

  • What is MacroGenics revenue?

    Latest MacroGenics annual revenue is $157.7 m.

  • What is MacroGenics revenue per employee?

    Latest MacroGenics revenue per employee is $478 k.

  • Who are MacroGenics competitors?

    Competitors of MacroGenics include MyoKardia, Athersys and Ironwood Pharmaceuticals.

  • Where is MacroGenics headquarters?

    MacroGenics headquarters is located at 9640 Medical Center Dr, Rockville.

  • Where are MacroGenics offices?

    MacroGenics has offices in Rockville and South San Francisco.

  • How many offices does MacroGenics have?

    MacroGenics has 3 offices.